Intermediate-Size Expanded Access Trial of Autologous Hybrid T REG /Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral Sclerosis
Latest Information Update: 18 Jan 2025
At a glance
- Drugs RAPA 501 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Expanded access
- Sponsors Rapa Therapeutics
- 15 Dec 2023 New trial record